Genentech's Tecentriq meets in third Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III IMpower130 trial as first-line treatment of stage IV non-squamous non-small cell lung

Read the full 408 word article

User Sign In